DGAP-News: Andera Partners' Portfolio Company T-knife Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
Retrieved on:
Tuesday, August 3, 2021
Medical specialties, Branches of biology, Clinical medicine, Immunology, Immune system, Cell signaling, T-cell receptor, T cell, TCR, Kite Pharma, Short course immune induction therapy, Andera Partners, T-knife Therapeutics, the HuTCR platform, ANDERA PARTNERS, T-KNIFE THERAPEUTICS, THE HUTCR PLATFORM
T-knife plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).
Key Points:
- T-knife plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).
- "We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates."
- "We are highly encouraged by the progress being made at T-knife to advance its important next-generation therapies."
- T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients.